基础胰岛素与二肽基肽酶－4抑制剂联合治疗2型糖尿病的临床观察

摘要

目的：观察基础胰岛素与二肽基肽酶－4抑制剂联合治疗2型糖尿病的临床疗效。方法：将80例2型糖尿病患者（空腹血糖＞11．1 mmol／L）以随机数字表法分为观察组与对照组各40例，观察组患者给予地特胰岛素与西格列汀联合治疗，对照组患者给予地特胰岛素与瑞格列奈联合治疗，观察2组患者的临床疗效。结果：观察组患者空腹及餐后2h血糖、糖化血红蛋白、血脂谱、体质量指数较治疗前明显下降（P＜0．05），且各项指标改善情况均优于对照组（P＞0．05）；2组患者胰岛β细胞功能均较治疗前明显下降，观察组改善情况优于对照组（P＜0．05）；2组患者不良反应均较少，差异无统计学意义（P＞0．05）；2组患者血糖达标率及血糖达标中位时间的差异有统计学意义（P＜0．05）。结论：基础胰岛素与二肽基肽酶－4抑制剂联合治疗2型糖尿病，具有较好的临床疗效，且安全性高，值得推广。%OBJECTIVE:To study the clinical efficacy of basic insulin plus DPP 4 inhibitors for type 2 diabetes mellitus.METHODS:80 patients with type 2 diabetes whose fasting blood glucose level was >11.1 mmol/L were randomly divided into either treatment group or control group of 40 cases each.The treatment group was given insulin plus sitagliptin while the control was group given insulin plus repaglinide.The clinical efficacy of the two groups was recorded.RESULTS: As compared with before treatment, the fasting blood glucose, and the postprandial blood glucose(2 hours after meal), HBA1C, blood lipid profile and body mass index ( BMI) in the treatment group decreased significantly(P0.05 );pancreatic beta cell function was significantly decreased in both groups after treatment as compared with before treatment, with the treatment group showing better improvement than in the control group( P0.05 ) .No statistically significant differences were noted between the two groups regarding the blood glucose target-meeting rate and the median time to meet blood glucose target(P<0.05).CONCLUSIONS:Basic insulin plus DPP 4 inhibitors is safe and effective for type 2 diabetes, thus the use of which is worthy of clinical recommendation.